Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$5.03
-$0.40(-10.55%)
At close: 4:00 PM EDT
$5.03
-$0.40(-10.55%)
Day’s Range― - ―
52-Week Range$2.00 - $17.96
Previous CloseN/A
Volume43.59K
Average Volume (3M)189.85K
Market Cap
$21.00M
Enterprise Value-$17.95M
Total Cash (Recent Filing)$29.05M
Total Debt (Recent Filing)$9.55M
Price to Earnings (P/E)―
Beta3.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,008,313
10 Day Avg. Volume63,343
30 Day Avg. Volume189,848
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.85
Enterprise Value/Revenue-1.01
Enterprise Value/Gross Profit-2.82
Enterprise Value/Ebitda13.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageManageable leverage gives Universe Pharmaceuticals greater financial flexibility than a heavily indebted business. The modest debt burden may reduce interest and refinancing pressure, helping preserve resources for operations and strategic investment while the company works to restore profitability.
Gross Margin RecoveryThe substantial gross-margin recovery indicates that product economics improved despite continuing losses. If maintained, better gross profitability could provide operating leverage as revenue stabilizes, although the company still needs further cost control before the improvement translates into positive earnings.
Expanded Pharmaceutical Intellectual PropertyAdding five patents broadens the company’s intellectual-property base and may strengthen its future pipeline in several therapeutic areas. This creates a potentially more differentiated platform for product development and partnerships, providing strategic upside beyond the existing manufacturing and distribution business.
Bears Say
Multi-year Revenue Contraction And Persistent LossesSustained revenue contraction combined with four consecutive annual losses signals that the current business model has not yet achieved durable commercial scale. Continued volume and earnings pressure can weaken reinvestment capacity and make the margin recovery difficult to sustain over the next several quarters.
Negative Cash GenerationPersistent negative operating and free cash flow means the business is consuming cash rather than internally funding operations and growth. Even with low leverage, continued losses could require external funding or use of balance-sheet resources, reducing financial flexibility and increasing execution risk.
Nasdaq Minimum-price Compliance RiskThe contingent reverse split indicates an ongoing risk to maintaining the U.S. listing and reflects pressure associated with Nasdaq minimum-price compliance. A required consolidation could complicate shareholder relations and capital-market access, while diverting management attention from operational recovery.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $17.96 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $21.00M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 5,008,313 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―